Compare MBUU & VOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MBUU | VOR |
|---|---|---|
| Founded | 1982 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 474.0M | 755.7M |
| IPO Year | 2013 | 2021 |
| Metric | MBUU | VOR |
|---|---|---|
| Price | $26.22 | $16.05 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 7 | 10 |
| Target Price | $32.43 | ★ $45.44 |
| AVG Volume (30 Days) | 275.7K | ★ 1.2M |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 127.74 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $807,561,000.00 | N/A |
| Revenue This Year | $1.44 | N/A |
| Revenue Next Year | $10.67 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $23.92 | $0.13 |
| 52 Week High | $39.65 | $49.95 |
| Indicator | MBUU | VOR |
|---|---|---|
| Relative Strength Index (RSI) | 50.81 | 55.16 |
| Support Level | $24.30 | $11.38 |
| Resistance Level | $27.81 | $16.88 |
| Average True Range (ATR) | 1.01 | 1.63 |
| MACD | 0.23 | 0.05 |
| Stochastic Oscillator | 66.67 | 50.81 |
Malibu Boats is a designer and manufacturer of power boats in the United States. It is a market leader in performance sport boats, sold under its Malibu and Axis brands. It acquired Cobalt Boats, a producer of sterndrive boats, in 2017, and Pursuit Boats, which makes high end offshore and outboard motorboats in 2018. In 2021, it purchased Maverick Boat Group, a seller of flat fishing boats, with exposure to bay, dual console, and center console boats. Malibu has also expanded into boat trailers and accessories, and in 2020, began producing its own engines for its performance sport boats.
Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of autoimmune diseases. Its program, telitacicept, is a potential first- and best-in-class dual BAFF/APRIL inhibitor designed to suppress the signaling pathways that drive the maturation, proliferation, and survival of harmful B cells, including self-reactive B cells, thereby reducing autoantibody production and preventing downstream tissue damage.